France· FR:60248840
TAFINLAR 75 mg, gélule
A medicinal product containing mésilate de dabrafénib, registered in France by NOVARTIS EUROPHARM (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE DE DABRAFÉNIB
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400927549731flacon(s) polyéthylène haute densité (PEHD) de 120 gélule(s)EUR 4.44
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mésilate de dabrafénib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTafinlarParanova Oy
- United KingdomTafinlar 75mg capsulesNovartis Pharmaceuticals UK Ltd
- CzechiaTAFINLARNovartis Europharm Limited, Dublin
- SwitzerlandTafinlar 75 mg, HartkapselnNovartis Pharma Schweiz AG
- IcelandTafinlarNovartis Europharm Limited*
- NetherlandsTafinlar 75 mg, harde capsulesNovartis Europharm Limited
- NorwayTafinlarNovartis Europharm Limited (1)
- PolandTafinlarNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Finlee, Tafinlar
- Liechtenstein · Finlee, Tafinlar
- Norway · Finlee, Tafinlar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/35592619-ec61-4402-8a34-12403688a3f3 GET /v1/drugs/35592619-ec61-4402-8a34-12403688a3f3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60248840",
"date_amm": "2013-08-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/13/865",
"substance": "MÉSILATE DE DABRAFÉNIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mésilate de dabrafénib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.